Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic failure of obinutuzumab due to massive third-space sequestration in a patient with high-burden follicular lymphoma: A rationale for therapeutic drug monitoring and dose intensification

Rong Xie, Qiang He, Hanheng Mai, Lili Feng, Yiwen Huang, Li Zhang, Ziqing Ma, Yuhong Ba, Kuntong Liu, Y. Lynn Wang, Ji Ma

Blood (2025) 146 (Supplement 1): 7131.

https://doi.org/10.1182/blood-2025-7131

Published: 2025

Journal Articles

Efficacy and safety of Golidocitinib-based first line regimen in peripheral T-cell lymphoma: A multicenter retrospective study

Zhumei Zhan, Peipei Li, Xianghua Wang, Changqing Zhen, Junqing Xu, Jie Yu, Ji Ma, Beibei Lv, Xin Liu, Ken H. Young, Xiaosheng Fang

Blood (2025) 146 (Supplement 1): 7157.

https://doi.org/10.1182/blood-2025-7157

Published: 2025

Journal Articles

Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates

Blood (2025) 146 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2025-1843

Published: 2025

Journal Articles

Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study

Rong Xie, Qiang He, Linna Xie, Lili Feng, Qi Kong, Kuntong Liu, Ziqing Ma, Yuhong Ba, Zonghong Li, Qian Wu, Tan Sang, Y. Lynn Wang, Ji Ma

Blood (2025) 146 (Supplement 1): 7221.

https://doi.org/10.1182/blood-2025-7221

Published: 2025

Journal Articles

A Prospective Study of Rituximab/Bendamustine and Rituximab/DHAP +/- Zanubrutinib Induction Therapy with or without ASCT in Young Newly Diagnosed Mantle Cell Lymphoma

Hui Wang, Lijie Xing, Dan Liu, Haichen Wei, Ke Lu, Qiang He, Linna Xie, Ji Ma, Lugui Qiu, Zengjun Li

Blood (2024) 144 (Supplement 1): 6307.

https://doi.org/10.1182/blood-2024-206243

Published: 2024

Journal Articles

Time-Limited of Zanubrutinib, Rituximab and Lenalidomide (ZR2) Regimen for the Treatment of Super-Elderly Diffuse Large B-Cell Lymphoma (DLBCL): A Prospective, Exploratory Clinical Study

Jie Zou, Xiaoning Yu, Xiaoxia Chu, Ji Ma, Zengjun Li, Chunyan Chen, Yan Liu, Jian Xing, Zhongliang Sun, Chunyan Ji, Jie Li

Blood (2024) 144 (Supplement 1): 1732.

https://doi.org/10.1182/blood-2024-207021

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome Combined with Cytarabine As Induction Therapy for Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia

Yun Wang, Weida Wang, Jingbo Xu, Ji Ma, Hua Wang, Bingyi Wu, Yuanbin Song, Weiran Lv, Lezong Chen, Jun Ma, Tiejun Gong, Yang Liang

Blood (2024) 144 (Supplement 1): 6074.

https://doi.org/10.1182/blood-2024-209055

Published: 2024

Journal Articles

Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling

Ji Ma, Qiang He, Qian Wu, Lili Feng, Y. Lynn Wang, Linna Xie

Blood (2024) 144 (Supplement 1): 1557.

https://doi.org/10.1182/blood-2024-204227

Published: 2024

Journal Articles

Interim Report of Bendamustine Plus Rituximab As First-Line Induction Therapy with or without Lenalidomide Maintenance Therapy in Chinese Patients with Indolent Non-Hodgkin's Lymphoma or Elderly Mantle Cell Lymphoma: Data from a Multi-Center Prospective Trial

Blood (2022) 140 (Supplement 1): 11962–11963.

https://doi.org/10.1182/blood-2022-162507

Published: 2022

Journal Articles

Untargeted Metabolomics of Cerebrospinal Fluid in Patients with Primary Central Nervous System Lymphoma

Xiaoyue Wang, Ji Ma, Liang Wang

Blood (2022) 140 (Supplement 1): 11921–11922.

https://doi.org/10.1182/blood-2022-162899

Published: 2022

Journal Articles

Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma

Qiang He, Linna Xie, Rongrong Zhao, Ji Ma, Hui Wang, Jie Li, Chuanli Zhao, Y. Lynn Wang, Zengjun Li

Blood (2022) 140 (Supplement 1): 6614–6615.

https://doi.org/10.1182/blood-2022-168859

Published: 2022

Journal Articles

A Multicenter, Single-Arm, Prospective Phase II Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Dignosed Primary Central Nervous System Lymphoma

Ji Ma, Qiang He, Ke Lu, Liang Wang

Blood (2022) 140 (Supplement 1): 3744–3745.

https://doi.org/10.1182/blood-2022-165720

Published: 2022

Journal Articles

SHP1 Loss Augments DLBCL Cellular Response to Ibrutinib: A Candidate Predictive Biomarker

Y. Lynn Wang, Ji Ma, Vinay Mallikarjuna, Pin Lu, Shengchun Wang, Sahar Poureghbali, Mariusz A Wasik, Reza Nejati, Wenjun Wu

Blood (2021) 138 (Supplement 1): 3490.

https://doi.org/10.1182/blood-2021-146086

Published: 2021

Journal Articles

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Craig W. Freyer, PharmD, Wenyan Ji, MA, Tara L. Cronin, BA, Swapna Thota, MD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Jeffrey Baron, PharmD, Mark Walsh, PharmD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 1361.

https://doi.org/10.1182/blood-2019-130582

Published: 2019

Journal Articles

Human Leukocyte Antigen-G Restores Immune Tolerance in Immune Thrombocytopenia

Qi Feng, Ji Ma, Xin Li, Ming Hou, Jun Peng, MD PhD

Blood (2018) 132 (Supplement 1): 3751.

https://doi.org/10.1182/blood-2018-99-115713

Published: 2018

Journal Articles

High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia

Yu Hou, Qi Feng, Miao Xu, Guo-sheng Li, Xue-na Liu, Zi Sheng, Hai Zhou, Ji Ma, Yu Wei, Yuan-xin Sun, Ying-yi Yu, Ji-hua Qiu, Lin-lin Shao, Xin-guang Liu, Ming Hou, Jun Peng

Blood (2016) 127 (12): 1587–1597.

https://doi.org/10.1182/blood-2015-10-674531

Published: 2016

Includes: Supplemental data

Journal Articles

Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia

Ji Ma, Yun-na Ning, Miao Xu, Yu Hou, Ning Wang, Xiao-yan Hou, Ying-yi Yu, Hui Li, Wei-dong He, Lin-lin Shao, Hai Zhou, Ya-nan Min, Xin-guang Liu, Yan Shi, Ping Qin, Cheng-shan Guo, Ming Hou, Jun Peng

Blood (2013) 122 (12): 2074–2082.

https://doi.org/10.1182/blood-2013-03-491555

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pharmacokinetic failure of obinutuzumab due to massive third-space sequestration in a patient with high-burden follicular lymphoma: A rationale for therapeutic drug monitoring and dose intensification

Efficacy and safety of Golidocitinib-based first line regimen in peripheral T-cell lymphoma: A multicenter retrospective study

Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates

Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study

A Prospective Study of Rituximab/Bendamustine and Rituximab/DHAP +/- Zanubrutinib Induction Therapy with or without ASCT in Young Newly Diagnosed Mantle Cell Lymphoma

Time-Limited of Zanubrutinib, Rituximab and Lenalidomide (ZR2) Regimen for the Treatment of Super-Elderly Diffuse Large B-Cell Lymphoma (DLBCL): A Prospective, Exploratory Clinical Study

Mitoxantrone Hydrochloride Liposome Combined with Cytarabine As Induction Therapy for Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia

Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling

Interim Report of Bendamustine Plus Rituximab As First-Line Induction Therapy with or without Lenalidomide Maintenance Therapy in Chinese Patients with Indolent Non-Hodgkin's Lymphoma or Elderly Mantle Cell Lymphoma: Data from a Multi-Center Prospective Trial

Untargeted Metabolomics of Cerebrospinal Fluid in Patients with Primary Central Nervous System Lymphoma

Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma

A Multicenter, Single-Arm, Prospective Phase II Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Dignosed Primary Central Nervous System Lymphoma

SHP1 Loss Augments DLBCL Cellular Response to Ibrutinib: A Candidate Predictive Biomarker

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Human Leukocyte Antigen-G Restores Immune Tolerance in Immune Thrombocytopenia

High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia

Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only